Understanding Tesamorelin Dosing in Research
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with an additional trans-3-hexenoic acid modification that enhances stability and bioavailability. It is the only GHRH analog to have received FDA approval (as Egrifta) for a specific clinical indication.
Mechanism of Action
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous hGH administration, tesamorelin preserves the natural pulsatile pattern of GH secretion and maintains the hypothalamic-pituitary feedback axis.
FDA-Approved Dosing (Egrifta)
The FDA-approved dosing for the clinical indication is:
- Dose: 2mg daily
- Administration: Subcutaneous injection in the abdomen
- Duration: Ongoing as indicated
Research Dosing Protocols
Standard Protocol
- Dose: 1-2mg daily
- Frequency: Once daily, typically morning
- Administration: Subcutaneous injection
- Duration: 12-26 weeks in clinical research
GH Response Timing
Peak plasma GH levels typically occur 15-45 minutes post-injection, with GH remaining elevated for approximately 2-3 hours. IGF-1 elevation is more sustained, typically reaching peak levels after 2-4 weeks of daily administration.
Clinical Trial Findings
Multiple clinical trials with 2mg daily dosing demonstrated significant effects on visceral adipose tissue reduction (averaging 15-18% decrease), improved lipid profiles, and enhanced trunk fat-to-lean mass ratios. Importantly, these effects occurred without significant changes in subcutaneous fat, glucose tolerance, or limb fat mass.
Combination Considerations
Tesamorelin acts through the GHRH receptor pathway, making it complementary to GHRP-class peptides like ipamorelin which act through the ghrelin/GHS-R pathway. Some research protocols examine this GHRH + GHRP combination approach. See our ipamorelin vs tesamorelin comparison.
Reconstitution
Reconstitute with bacteriostatic water per vial label instructions. See our reconstitution guide for general peptide preparation protocols.
Storage
Store lyophilized tesamorelin at 2-8°C (refrigerator). Do not freeze. Reconstituted solution at 2-8°C, use within 2-3 weeks. See storage guide.
For research and educational purposes only. Tesamorelin is sold for research use only. Visit COAs for purity verification.